Millions more monkeypox vaccine and antiviral courses coming to states next week, but will it be enough?
HHS said this morning that beginning next Monday it will make available an additional 1.8 million intradermal doses (5 doses per vial) of Bavarian Nordic’s Jynneos vaccine, although only states and other jurisdictions that have used up 90% of their current supplies can obtain the new doses.
The push for more doses and the switch to intradermal doses comes as top FDA leaders wrote to Bavarian Nordic last week saying that the available vaccine doses through the end of this year “is estimated to only be sufficient to immunize half of the individuals at highest risk for monkeypox.” FDA commissioner Rob Califf and CBER director Peter Marks also wrote that they’ve ruled out using any other vaccines at the moment, but noted that the intradermal approach with Jynneos “produced a very similar immune response to subcutaneous administration.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.